Rallybio Corporation develops therapies for severe and rare diseases as a clinical-stage biotechnology company. News about RLYB centers on RLYB116, a differentiated complement component 5 inhibitor for complement-mediated diseases with an initial focus on immune platelet transfusion refractoriness and refractory antiphospholipid syndrome, and on RLYB332, a preclinical long-acting matriptase-2 antibody for diseases of iron overload.
Recurring updates also cover clinical data, operating and financial results, material agreements involving pipeline-related assets such as REV102, shareholder voting matters, governance actions, Nasdaq listing matters and capital-structure changes affecting the company's common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.